scholarly journals Non-Hodgkin's lymphoma presenting with pulmonary involvement

2022 ◽  
Vol 0 (0) ◽  
pp. 0
Author(s):  
KM Bhargav ◽  
MShri Ramya ◽  
Alladi Mohan ◽  
N Rukmangada ◽  
TC Kalawat ◽  
...  
Keyword(s):  
Hodgkin’S Lymphoma ◽  
Pulmonary Involvement ◽  
Hodgkin's Lymphoma ◽  
Non Hodgkin’S Lymphoma ◽  
Non Hodgkin's Lymphoma

scholarly journals Thoracic Actinomycosis in a Patient with Pulmonary Involvement Caused by Non-Hodgkin's Lymphoma

1996 ◽  
Vol 22 (4) ◽  
pp. 731-732 ◽  
Author(s):  
J. A. E. Batt ◽  
J. Brendan ◽  
M. Mullen ◽  
H. Vellend ◽  
M. S. Balter
Keyword(s):  
Hodgkin’S Lymphoma ◽  
Pulmonary Involvement ◽  
Hodgkin's Lymphoma ◽  
Thoracic Actinomycosis ◽  
Non Hodgkin’S Lymphoma ◽  
Non Hodgkin's Lymphoma

Non-Hodgkin's Lymphoma of the Lung

1988 ◽  
Vol 33 (2) ◽  
pp. 243-245 ◽  
Author(s):  
D.L. Farquhar ◽  
G.K. Crompton ◽  
M.A. McIntyre ◽  
R.C.F. Leonard
Keyword(s):  
Lymph Nodes ◽  
Hodgkin’S Lymphoma ◽  
Lung Parenchyma ◽  
Pulmonary Involvement ◽  
Hodgkin's Lymphoma ◽  
Computerised Tomography ◽  
Extensive Disease ◽  
Non Hodgkin’S Lymphoma ◽  
Non Hodgkin's Lymphoma

Non-Hodgkin's lymphoma (NHL) commonly presents with extensive disease involving extranodal tissues. Involvement of the mediastinal and hilar lymph nodes, pleura and lung parenchyma are recognised complications although their incidence is uncertain. However pulmonary involvement is undoubtedly much less common than involvement at other extra nodal sites. Histologically proven NHL limited to the lung parenchyma, after full staging including computerised tomography and marrow trephines, is extremely rare. We report on two such cases and review the literature.

scholarly journals Non-Hodgkin's Lymphoma Accompanied by Pulmonary Involvement with Diffuse Ground-Glass Opacity on Chest CT: A Report of 2 Cases

2009 ◽  
Vol 48 (2) ◽  
pp. 105-109 ◽  
Author(s):  
Hirokazu Tokuyasu ◽  
Tomoya Harada ◽  
Etsuko Watanabe ◽  
Hirokazu Touge ◽  
Yuji Kawasaki ◽  
...  
Keyword(s):  
Hodgkin’S Lymphoma ◽  
Ground Glass Opacity ◽  
Pulmonary Involvement ◽  
Chest Ct ◽  
Hodgkin's Lymphoma ◽  
Ground Glass ◽  
Non Hodgkin’S Lymphoma ◽  
Non Hodgkin's Lymphoma

Chemotherapy of advanced non-Hodgkin's lymphoma

1979 ◽  
Vol 8 (3) ◽  
pp. 667-684 ◽  
Author(s):  
Arthur T. Skarin ◽  
George P. Canellos
Keyword(s):  
Hodgkin’S Lymphoma ◽  
Hodgkin's Lymphoma ◽  
Non Hodgkin’S Lymphoma ◽  
Non Hodgkin's Lymphoma

Antiphospholipid Antibodies: Prevalence, Clinical Significance and Correlation to Cytokine Levels in Acute Myeloid Leukemia and Non-Hodgkin’s Lymphoma

1993 ◽  
Vol 70 (04) ◽  
pp. 568-572 ◽  
Author(s):  
Roberto Stasi ◽  
Elisa Stipa ◽  
Mario Masi ◽  
Felicia Oliva ◽  
Alessandro Sciarra ◽  
...  
Keyword(s):  
Acute Myeloid Leukemia ◽  
Clinical Significance ◽  
Antiphospholipid Antibodies ◽  
Myeloid Leukemia ◽  
Hodgkin’S Lymphoma ◽  
Hodgkin's Lymphoma ◽  
Tnf Alpha ◽  
Non Hodgkin’S Lymphoma ◽  
Non Hodgkin's Lymphoma ◽  
Acute Myeloid

SummaryThis study was designed to explore the prevalence and clinical significance of elevated antiphospholipid antibodies (APA) titres in patients affected by acute myeloid leukemia (AML) and highgrade non-Hodgkin’s lymphoma (NHL). We also analyzed possible correlations with circulating levels of interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-alpha), and the soluble form of the receptor for interleukin-2 (sIL-2r). Nineteen patients with de novo AML and 14 patients with newly-diagnosed NHL were investigated. Tests for APA included the measurement of anticardiolipin antibodies (ACA) with a solid-phase immunoassay, and the detection of the lupus-like anticoagulant (LA) activity. Five patients with AML (26.3%) and 5 patients with NHL (35.7%) presented elevated APA at diagnosis, as compared to 3 of 174 persons of the control group (p <0.0001). APA titres became normal in all patients responding to treatment, whereas nonresponders retained elevated levels. In addition, 6 patients (4 with AML and 2 with NHL), who had normal APA at diagnosis and were either refractory to treatment or in relapse, subsequently developed LA and/or ACA positivity. At presentation, the mean levels of IgG- and IgM-ACA in patients were not significantly different from Controls, and concordance between ACA and LA results reached just 30%. With regard to the clinical course, we were not able to detect any statistically significant difference between patients with normal and elevated APA. Pretreatment concentrations of IL-6 and TNF-alpha in AML, and sIL-2r in NHL were found significantly elevated compared to Controls (p = 0.003, p = 0.009 and p = 0.024 respectively). In addition, the levels of these cytokines correlated with IgG-ACA at the different times of laboratory investigations. These results demonstrate that APA may have a role as markers of disease activity and progression in some haematological malignancies.

Sign in / Sign up

Export Citation Format

Share Document